Journal•ISSN: 0963-0643
Current Opinion in Urology
Lippincott Williams & Wilkins
About: Current Opinion in Urology is an academic journal published by Lippincott Williams & Wilkins. The journal publishes majorly in the area(s): Prostate cancer & Medicine. It has an ISSN identifier of 0963-0643. Over the lifetime, 2593 publications have been published receiving 44950 citations. The journal is also known as: Curr Opin Urol.
Topics: Prostate cancer, Medicine, Bladder cancer, Cancer, Cystectomy
Papers published on a yearly basis
Papers
More filters
TL;DR: The designs of existing commercial RMIS systems are not conducive for force feedback, and creative solutions are needed to create compelling tactile feedback systems.
Abstract: Purpose of Review
Robot-assisted minimally invasive surgery (RMIS) holds great promise for improving the accuracy and dexterity of a surgeon while minimizing trauma to the patient. However, widespread clinical success with RMIS has been marginal. It is hypothesized that the lack of haptic (force and tactile) feedback presented to the surgeon is a limiting factor. This review explains the technical challenges of creating haptic feedback for robot-assisted surgery and provides recent results that evaluate the effectiveness of haptic feedback in mock surgical tasks.
551 citations
TL;DR: Benign prostatic hyperplasia afflicts the majority of elderly men, and if current rates of surgery persist, the average 40-year-old man in the United States will have a 30 to 40 per cent chance of undergoing a prostatectomy if he survives to age 80.
Abstract: Recent research clearly shows that symptoms of benign prostatic hyperplasia are frequent among older men, many of whom do not seek medical attention. Older men and perhaps non-smokers are at higher risk of benign prostatic hyperplasia, which progresses slowly with waxing and waning symptoms and a relatively low rate of complications.
263 citations
TL;DR: The best characterization of prostate cancer in individual patients will most likely result from a multiparametric (MRI/MRSI/DTI/DCE) exam using 3T magnetic resonance scanners but questions remain as to how to analyze and display this large amount of imaging data, and how to optimally combine the data for the most accurate assessment.
Abstract: Purpose of reviewThe purpose of this article is to review the current status of advanced MRI techniques based on anatomic, metabolic and physiologic properties of prostate cancer with a focus on their impact in managing prostate cancer patients.Recent findingsProstate cancer can be identified based
229 citations
TL;DR: In the future, MRI–ultrasound fusion for lesion targeting is likely to result in fewer and more accurate prostate biopsy than the present use of systematic biopsies with ultrasound guidance alone.
Abstract: Purpose of reviewProstate cancer (CaP) may be detected on MRI. Fusion of MRI with ultrasound allows urologists to progress from blind, systematic biopsies to biopsies, which are mapped, targeted and tracked. We herein review the current status of prostate biopsy via MRI/ultrasound fusion.Recent find
207 citations
TL;DR: It is argued that a continuous multivariable prediction model, such as a nomogram, is the most appropriate and accurate way to select high-risk patients.
Abstract: Purpose of review We outline a generic approach to using a nomogram to predict a continuous probability of failure in high-risk patients (rather than putting patients into groups), in order to identify patients whose risk exceeds a cutoff point. We discuss the goals of any staging system, what markers should be included, and models of markers. Recent findings Selection of high-risk patients for any cancer has traditionally been accomplished by the creation of risk groups, or perhaps clinical stages. Ideally, high-risk patients should be identified as accurately as possible, because of the treatment and psychological implications for the patient. We argue that a continuous multivariable prediction model, such as a nomogram, is the most appropriate and accurate way to select high-risk patients. This type of model predicts outcome more accurately than risk grouping or staging systems. As an example, we use our preoperative prostatic specific antigen recurrence nomogram to identify patients at high risk of biochemical failure, who are in need of an effective neoadjuvant therapy. Summary It will follow from our discussion that identification of high-risk patients should follow four simple steps. First, select the endpoint of interest for the trial or the patient. Second, select the method that predicts the endpoint as accurately as possible. Third, determine the cutoff of predicted probability beyond which it makes sense to give the patient experimental therapy. Fourth, offer the novel therapy to the patient whose prediction of the endpoint, using the most accurate prediction method, exceeds the threshold.
190 citations